Failure to Monitor Psychotropic Side Effects and Antiseizure Drug Levels
Summary
The facility failed to monitor, identify, and document side effects of medications for residents receiving psychotropic drugs. R82, who had diagnoses including anxiety disorder, psychosis, schizophrenia, depression, and extrapyramidal and movement disorder, was observed on multiple occasions with excessive drooling while talking, repeatedly wiping his mouth, and showing moisture marks on his shirt below his mouth. He stated that he could not control the drooling and felt embarrassed by it. His POS showed he was receiving Clozapine 50 mg, three tablets in the morning and five tablets at bedtime, and an order to monitor for side effects of antipsychotic medication was documented. However, the TAR for January 2026 showed no side effects documented for the month, despite the observations and staff statements that drooling is a common side effect of antipsychotic medication. R93, who had diagnoses including dementia, depressive disorder, severe intellectual disabilities, and schizoaffective disorder, bipolar type, was observed pacing, repeatedly stating he was going to the gas station and asking what he needed to buy, while also drooling excessively with moisture marks on his shirt. On additional observations, he was standing near the nurse's station and drooling excessively. His POS showed he received Clozapine 50 mg at bedtime, Olanzapine 20 mg half tablet twice daily, and Benztropine Mesylate 0.5 mg twice daily for drug-induced extrapyramidal symptoms, with an order to monitor for side effects of antipsychotic medication. His care plan directed staff to monitor for side effects and effectiveness every shift, but the TAR documented no side effects for the month reviewed. R182, who had diagnoses including depressive disorder, anxiety disorder, extrapyramidal and movement disorder, schizophrenia, and schizoaffective disorder, was also observed with excessive drooling while standing by his doorway and constantly wiping his mouth while talking. He said he was embarrassed by the drooling and that his appearance mattered to him. His POS showed he received Clozapine 100 mg every morning and 200 mg at bedtime, along with Benztropine Mesylate 1 mg twice daily, and an order to monitor for side effects of antipsychotic medication. His care plan also required monitoring for side effects and effectiveness every shift, but the TAR again showed no side effects documented for the month reviewed. In addition, R51, who had a seizure disorder and history of convulsions, was receiving Dilantin for seizure management. His last Dilantin blood level was 4.0, below the reference range of 10.0 to 20.0, and the physician ordered a dosage increase and a repeat blood level in two weeks. The repeat level was not completed as ordered, and the EMR showed the lab order remained incomplete as of the survey date.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.